Proteasome-mediated reduction in proapoptotic molecule Bim renders CD4⁺CD28null T cells resistant to apoptosis in acute coronary syndrome. by Kovalcsik, E et al.
Apoptosis resistance of CD28null T cells in ACS 
Proteasome-mediated reduction in pro-apoptotic molecule Bim renders CD4+CD28null T cells 
resistant to apoptosis in acute coronary syndrome 
 
 
Kovalcsik: Apoptosis resistance of CD28null T cells in ACS 
 
Edit Kovalcsik PhD1, Ricardo F. Antunes PhD1, Paramita Baruah MD, PhD1, Juan Carlos Kaski 
MD, DSc, FRCP, FESC, FACC, FAHA1, Ingrid E. Dumitriu MD, PhD1* 
 
1Cardiovascular and Cell Sciences Research Institute, St. George’s University of London, Cranmer 
Terrace, SW17 0RE, London, UK 
 
*Corresponding author: Ingrid E. Dumitriu, Cardiovascular and Cell Sciences Research Institute, 
St. George’s University of London, Cranmer Terrace, SW17 0RE, London, UK; Phone: 
00442087252808; Fax: 00442087253328; e-mail: i.dumitriu@sgul.ac.uk 
 
 
 
 
Word count: 7994 
 
Journal subject codes pertaining to article 
[3] Acute coronary syndromes 
[131] Apoptosis 
[137] Cell biology/structural biology 
Apoptosis resistance of CD28null T cells in ACS !
! "!
Abstract 
Background: The number of CD4+CD28null (CD28null) T cells, a unique subset of T lymphocytes 
with proinflammatory and cell-lytic phenotype, increases markedly in patients with acute coronary 
syndrome (ACS). ACS patients harbouring high numbers of CD28null T cells have increased risk of 
recurrent severe acute coronary events and unfavourable prognosis. The mechanisms that govern 
the increase in CD28null T cells in ACS remain elusive. We investigated whether apoptosis 
pathways regulating T cell homeostasis are perturbed in CD28null T cells in ACS. 
Methods and Results: We found that CD28null T cells in ACS were resistant to apoptosis 
induction via Fas-ligation or ceramide. This was due to a dramatic reduction in pro-apoptotic 
molecules Bim, Bax and Fas in CD28null T cells, whilst anti-apoptotic molecules Bcl-2 and Bcl-xL 
were similar in CD28null and CD28+ T cells. We also show that Bim is phosphorylated in CD28null 
T cells and degraded by the proteasome. Moreover, we demonstrate for the first time that 
proteasomal inhibition restores the apoptosis sensitivity of CD28null T cells in ACS. 
Conclusions: We show that CD28null T cells in ACS harbour marked defects in molecules that 
regulate T cell apoptosis, which tips the balance in favour of anti-apoptotic signals and endows 
these cells with resistance to apoptosis. We demonstrate that inhibition of proteasomal activity 
allows CD28null T cells to regain sensitivity to apoptosis. A better understanding of the molecular 
switches that control apoptosis sensitivity of CD28null T cells may reveal novel strategies for 
targeted elimination of these T cells in ACS patients. 
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Introduction 
 
Myocardial infarction and stroke caused by atherosclerosis are the most frequent cardiovascular 
causes of death and disability in the world despite progress in prevention and therapy1. Recent 
evidence clearly implicates the innate and adaptive immune system in the pathogenesis of 
atherosclerosis2. T lymphocytes, the main orchestrators of adaptive immune responses, have 
pivotal roles in atherosclerosis. In particular, pro-inflammatory CD4+ T lymphocytes such as T 
helper 1 (Th1) cells have been shown to promote atherosclerosis in animal models and constitute 
the predominant T cells in human atherosclerotic plaques3-5. We and others have demonstrated that 
CD4+CD28null T cells, a unique subset of Th1 lymphocytes characterised by the lack of co-
stimulatory receptor CD28, are present in high numbers in the circulation and atherosclerotic 
plaques of patients with acute coronary syndrome (ACS)6-8, whilst these cells are not present in 
healthy individuals. Moreover, CD4+CD28null T cells (from now on abbreviated as CD28null T cells) 
produce higher levels of inflammatory cytokines interferon-! (IFN-!) and tumour necrosis factor-" 
(TNF-") than conventional CD4+CD28+ (CD28+) T cells6,9. In stark contrast to CD28+ T 
lymphocytes, CD28null T cells release cytotoxic molecules (i.e. perforin and granzymes)6 that are 
instrumental in killing endothelial and vascular smooth muscle cells in vitro10. These properties 
suggest that CD28null T cells have harmful effects in atherosclerosis, although a direct causal link is 
yet to be established as this subset of T cells is present only in humans with an equivalent 
population absent in mice. Recently, we were the first to show that the distinguishing feature 
between CD28null and conventional CD28+ T cells in ACS patients is a significantly higher 
expression on CD28null T cells of alternative co-stimulatory receptors 4-1BB and OX406. We 
further demonstrated that 4-1BB and OX40 have critical roles in regulating the production of 
inflammatory cytokines IFN-! and TNF-" and perforin release from CD28null T cells in ACS6. In 
addition to their roles in T cell co-stimulation, 4-1BB and OX40 are important for the survival of T 
cells11,12. As mentioned, ACS patients are known to harbour significantly higher numbers of 
CD28null T cells compared to stable angina (SA) patients and healthy subjects8,13. Importantly, ACS 
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patients with higher numbers of CD28null T cells have increased risk for recurrent severe acute 
coronary events and unfavourable prognosis13. This study also demonstrated that the number of 
CD28null T cells does not change during the course of the acute coronary event and up to two years 
afterwards. Thus understanding the precise mechanisms that lead to accumulation of CD28null T 
cells in ACS may reveal targets for novel therapies to prevent accumulation of these inflammatory 
cells. 
T cell homeostasis is maintained by elimination of unwanted T cells via apoptotic cell death. 
Whether a cell survives or succumbs to apoptosis depends on a fine balance between pro- and anti-
apoptotic signals14. Two main albeit converging apoptosis pathways have been well characterised: 
extrinsic (death-receptor-dependent) and intrinsic (mitochondrial-dependent) apoptosis14. The 
ultimate event in both pathways is activation of caspases, a family of cysteine proteases that cleave 
essential cellular targets, ultimately resulting in cell death. Fas (CD95) is the prototypical death 
receptor in the extrinsic apoptosis pathway15. Upon binding to its ligand, FasL (CD95L), Fas 
transmits a death signal to the cell via its intracellular death domain. The mitochondrial-dependent 
apoptosis pathway is regulated by Bcl-2 (B cell lymphoma-2) family members16. This includes 
anti-apoptotic (pro-survival) members with Bcl-2 and Bcl-xL as prototypic molecules, and pro-
apoptotic members such as Bim and Bax17,18. It has been suggested that Bax and its homologues 
are maintained in an inactive state by association with the anti-apoptotic Bcl-2 members (Bcl-2, 
Bcl-xL) at the mitochondrial membrane and this ‘happy balance’ must be overcome for apoptosis 
to occur17. This is primarily accomplished by Bim, which frees Bax from its complex with Bcl-
2/Bcl-xL in response to death signals19, thereby allowing Bax to exert its pro-apoptotic actions. 
We hypothesised that induction of apoptosis, which mediates elimination of T cells is dysregulated 
in CD28null T cells, and this could explain their accumulation in ACS patients. With this in view, 
we investigated the sensitivity of CD28null T cells from ACS patients to apoptosis. We provide 
novel evidence that, in ACS, CD28null T cells are resistant to apoptosis. We further demonstrate 
that the resistance to apoptosis is due to preponderance of anti-apoptotic signals in CD28null T cells 
as a result of a marked reduction in pro-apoptotic molecules Bim and Bax and the death receptor 
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Fas. Critically, we propose a novel mechanism that links Bim phosphorylation and its subsequent 
degradation by the proteasome as a key event that governs the loss of apoptosis sensitivity in 
CD28null T cells in ACS patients. Our data suggest for the first time that proteasome inhibition 
restores apoptosis sensitivity in CD28null T cells, which could potentially open new therapeutic 
avenues to eliminate these cells. 
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Methods 
Patient population 
Peripheral blood was obtained from patients with a diagnosis of ACS (STEMI and NSTEMI) and 
patients with stable angina (SA). The number of patients used in individual experiments is 
specified in the figure legends. Blood samples were collected 4-12h from the onset of chest pain. 
The demographic details and clinical characteristics of patients used to compare the levels of 
apoptotic molecules in CD28null T cells from ACS and SA patients are provided in Supplemental 
Table 1. Patients with evidence of infectious diseases, malignancies, haematologic or immunologic 
disorders, treatment with anti-inflammatory drugs other than aspirin, and an ejection fraction <40 
were excluded. The study was approved by the local research ethics committee; informed consent 
was obtained from all study subjects. 
Flow cytometric analysis 
The following antibodies were used: CD4-FITC, CD28-APC, Bcl-2-PE (all from BD Biosciences), 
Fas/CD95-PE, FasL(CD95L)-PE (eBiosciences), and Bcl-xL-PE (Abcam). Purified Bim (BD 
Biosciences) and purified Bax (R&D Systems) were used followed by labelling with donkey anti-
rabbit-PE (eBiosciences). Surface and intracellular staining were performed in accordance with the 
manufacturer’s instructions. Briefly, 100µl of blood was incubated with antibodies for 30-40min; 
red blood cells were lysed using Lyse/Fix buffer (BD Biosciences). For intracellular staining, cells 
were fixed and permeabilised using the Cytofix/Cytoperm buffer (BD Biosciences) prior to 
addition of antibodies for Bcl-2, Bcl-xL, Bim and Bax. Samples were acquired on a FACSCalibur 
(BD Biosciences) and data was analysed using the FlowJo software. Mean fluorescence intensity 
(MFI) was calculated by subtracting the MFI of samples stained with isotype control antibodies 
from the MFI of samples stained with specific antibodies. 
Cell isolation 
Histopaque (Sigma) was used to isolate peripheral blood mononuclear cells (PBMCs). CD4+ T 
cells were sorted by negative selection using the CD4+ T cell isolation kit II (Miltenyi Biotech) as 
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per the manufacturer’s instructions. The purity of sorted CD4+ T cells was 90-95%. CD28null and 
CD28+ T cells were sorted from the purified CD4+ T cells using the CD28 Microbead kit II 
(Miltenyi Biotech) as per the manufacturer’s instructions. The purity of sorted cells CD28null and 
CD28+ T cells ranged between 85-95% (Supplemental Figure 1). 
T cell activation and proliferation assays 
PBMCs were cultured at 5x105 cells per well in 96-well U-bottomed plates (Nunc) in the presence 
or absence of 2ug/ml plate-bound anti-CD3 antibodies (eBioscience) for 4 days before detection of 
apoptotic molecules as described for whole blood samples. Cells were cultured in RPMI 1% 
Penicillin/Streptomycin/L-glutamine (all from Gibco) supplemented with 5% pooled human AB 
serum (Lonza) and 25IU/ml interleukin-2 (IL-2, Roche). To assess the proliferation of CD28null and 
CD28+ T cells from ACS patients, T cells were labelled with 1µM CFSE (carboxyfluorescein 
succinimidyl ester) and stimulated with 2ug/ml plate-bound anti-CD3 antibodies (eBioscience), as 
previously described20. Cells were cultured in RPMI 1% Penicillin/Streptomycin/L-glutamine (all 
from Gibco) supplemented with 5% pooled human AB serum (Lonza) and 25IU/ml interleukin-2 
(IL-2, Roche) for 4 days. Proliferation as visualised by CFSE-dilution was quantified by flow 
cytometry. 
PhosFlow analysis of ERK1/2 signalling and Bim phosphorylation 
The following phospho site specific antibodies were used for detection of phosphorylated ERK1/2 
and Bim: anti-phospho-ERK1/2 (pT202/pY204) (BD Biosciences) and anti-phospho-Bim (pS65, 
Abcam). CD28null and CD28+ T cells purified by magnetic sorting were either left unstimulated or 
stimulated by CD3 cross-linking with monoclonal antibodies for 15min at 37ºC. Where indicated, 
cells were pre-incubated for 1 hour with the ERK1/2 specific inhibitor PD184352 (10µM, Sigma) 
or the proteasomal inhibitor MG-132 (10µM, Merck Millipore) followed by activation with anti-
CD3 antibodies in the continuous presence of the inhibitor. Cells were fixed with BD Cytofix 
Fixation buffer for 10min at 37ºC and then permeabilised with BD PhosFlow Perm buffer III for 
30min on ice prior to staining with phospho site specific antibodies, as per the manufacturer’s 
recommendations. 
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Apoptosis assays 
Sorted CD28null and CD28pos T cells were cultured at 5x104 cells per well in 96-well U-bottomed 
plates (Nunc) in serum-free X-Vivo medium (Lonza) supplemented with 1% 
Penicillin/Streptomycin/L-glutamine and 25IU/ml IL-2. For apoptosis induction cells were treated 
with 100ng/ml of anti-Fas clone CH11 antibody (Millipore) or 50µM C2-ceramide (Enzo Life 
Sciences). Apoptotic cells were measured at 20 hours using annexin V-FITC and 7-AAD (BD 
Biosciences) as per the manufacturer’s instructions. In some experiments, cells were treated with 
5µg/ml, 10µg/ml, 30µg/ml and 90ug/ml Atorvastatin®Pfizer (Selleckchem) or Rosuvastatin 
(Selleckchem) and cultured for 48 hours prior to apoptosis detection. Statins were purchased as 
reconstituted pure active compound. Where indicated, cells were pre-treated with the ERK1/2 
specific inhibitor PD184352 (5µM, Sigma) or the proteasomal inhibitor MG-132 (10nM, Merck 
Millipore) prior to CH11 treatment. Induction of apoptosis as a percentage was calculated as 
follows: 100x(percent apoptotic cells with CH11 - percent apoptotic cells without CH11)/(percent 
apoptotic cells without CH11).  Where indicated, normalisation of apoptosis was performed to pool 
data from different patients. The percentage of CD28pos apoptotic cells in samples treated with 
CH11 alone was normalised to 100. All other samples were normalised accordingly. 
Statistical analysis 
Categorical data were analysed by the #2-test. Statistically significant differences were determined 
using the Student’s t-test, ANOVA with post-test multiple comparisons or Wilcoxon matched-pairs 
signed rank test (as indicated in the Figure legends). Probability values (p) of less than 0.05 were 
considered statistically significant. Statistical analysis was performed using the GraphPad Prism 
software version 5.02 and 6.04. 
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Results 
CD28null T cells from ACS patients are resistant to apoptosis. 
Two features led us to hypothesise that CD28null T cells in ACS patients have alterations in 
apoptosis sensitivity: i) their number is increased8; and ii) these cells express higher levels of 
alternative co-stimulatory receptors 4-1BB and OX406, that have been shown to promote survival 
of other subsets of T lymphocytes11,12. To verify this hypothesis we examined the response of 
CD28null T cells to apoptosis induction. For this purpose, we treated purified CD28null and CD28+ T 
cells with CH11, a widely used agonistic anti-Fas antibody that triggers apoptosis in T cells by 
mimicking the effect of Fas ligation by FasL21,22. Apoptosis induction was quantified using 
Annexin-V (AxV) and 7-AAD. As expected, CH11 treatment induced apoptosis in conventional 
CD28+ T cells, as quantified by an increase in both early (AxV+7-AAD-) and late (AxV+7-AAD+) 
apoptotic cells (Figure 1A,B). In contrast, CD28null T cells exhibited significantly lower induction 
of apoptosis (both early and late) upon CH11 treatment in comparison to conventional CD28+ T 
cells (n=18, p<0.001, Figure 1A-C). We next examined whether the resistance of CD28null T cells 
to apoptosis induction via Fas ligation extended to other triggers of apoptosis. To test this, purified 
CD28null and CD28+ T cells were treated with C2-ceramide, a membrane-permeable ceramide 
analogue that has been suggested to induce apoptosis via the mitochondrial pathway through 
release of cytochrome c from the mitochondria23. As observed with CH11, C2-ceramide treatment 
resulted in a good induction of early and late apoptosis in CD28+ T cells (Figure 2A,B). In keeping 
with our results with CH11, CD28null T cells from ACS patients underwent significantly less 
apoptosis in response to C2-ceramide compared to CD28+ T cells (n=10, p<0.005 for early 
apoptosis and p<0.05 for late apoptosis, Figure 2A-C). 
It has been suggested that statins could induce apoptosis of CD28null T cells24. To test this, we 
cultured purified CD28null and CD28+ T cells either alone or in the presence of increasing 
concentrations of Atorvastatin or Rosuvastatin for 48 hours and quantified apoptosis induction. At 
all concentrations tested (5, 10, 30 and 90µg/ml), Atorvastatin and Rosuvastatin did not induce 
significant apoptosis in either CD28null or CD28+ T cells (Supplemental Figure 2A,B). 
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Noteworthy, the concentration of statins used in these experiments corresponded to plasma 
concentrations reached in patients on treatment with statins25. Furthermore, the highest 
concentration tested was well above the maximum recommended dose of 80mg Atorvastatin or 
40mg Rosuvastatin. These results demonstrate that statins do not induce apoptosis in CD28null T 
cells. 
Another reason for an increase in the number of CD28null T cells in ACS patients may be 
differences in the proliferation of CD28null and CD28+ T cells. Therefore, we quantified the 
proliferation of sorted CD28null and CD28+ T cells following stimulation with plate-bound anti-
CD3 cross-linking antibodies using the CFSE-dilution method. As seen in Supplemental Figure 3, 
CD28+ T cells proliferated efficiently in response to anti-CD3 antibodies. Indeed, more than 80% 
of CD28+ T cells exhibited CFSE dilution and had undergone 1 to 5 division rounds. In contrast, 
CD28null T cells had a slower division rate and proliferated significantly less than CD28+ T cells. 
CD28null T cells from ACS patients express low levels of death receptor Fas and pro-apoptotic 
molecules Bim and Bax. 
Following on our findings that CD28null T cells in ACS are resistant to apoptosis, we further 
investigated the mechanisms underlying the apoptosis resistance of this cell subset. Whether cells 
undergo apoptosis or survive depends on the balance between pro- and anti-apoptotic signals. We 
therefore examined the expression of death receptor Fas and its ligand FasL, as well as pro-
apoptotic (Bim and Bax) and anti-apoptotic (Bcl-2, Bcl-xL) molecules in circulating CD28null T 
cells from ACS patients (n=25). We analysed CD28null T cells directly ex vivo by staining fresh 
blood samples with monoclonal antibodies. We found that CD28null T cells have significantly 
reduced levels of Fas compared to conventional CD28+ T cells, while there was no difference in 
FasL expression (p<0.001 for Fas, Figure 3A,B). In addition, levels of pro-apoptotic proteins Bim 
and Bax were significantly decreased in CD28null T cells in comparison to CD28+ T cells (p<0.001, 
Figure 3A,B). In contrast, the anti-apoptotic molecules Bcl-2 and Bcl-xL were expressed at similar 
levels in CD28null T cells and their conventional CD28+ counterparts (Figure 3A,B). These results 
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demonstrate that the balance between pro- and anti-apoptotic molecules is altered in favour of anti-
apoptotic signals in CD28null T cells in ACS. 
CD28null T cells fail to upregulate pro-apoptotic molecules Bim and Bax upon activation. 
Activation of T cells is known to sensitise them to apoptosis14,26. We therefore investigated the 
impact of T cell activation on the expression of Fas, Bim and Bax pro-apoptotic molecules in 
CD28null T cells from ACS patients. For this purpose, cells were cultured in vitro for four days in 
the presence or absence of signals that activate T cells (i.e. anti-CD3 cross-linking antibodies). We 
showed that unstimulated CD28null T cells from ACS patients maintained low levels of Fas, Bim 
and Bax following 4 days of culture (Supplemental Figure 4A-C), in line with our observations 
on fresh cells (Figure 3). Following activation, Fas expression reached similar levels on the two T 
lymphocyte subsets (Supplemental Figure 4A). Noteworthy, even upon activation, CD28null T 
cells from ACS patients failed to up-regulate pro-apoptotic molecules Bim and Bax to levels 
comparable to conventional CD28+ T cells (Supplemental Figure 4B,C). No differences were 
noted in the expression of FasL and anti-apoptotic molecules Bcl-2 and Bcl-xL in cultured CD28null 
and CD28+ T cells whether the cells were activated or not, similar to our data on fresh T cells.  
Bim and Bax are markedly lower on CD28null T cells in ACS compared to SA. 
In comparison to healthy individuals, the number of circulating CD28null T cells increases not only 
in ACS but also in SA patients, albeit at lower levels than in ACS13. We therefore investigated 
whether the alterations in apoptotic molecules that we identified in ACS were also present in 
CD28null T cells from patients with SA. There was no significant difference in the demographic and 
clinical characteristics of the two patient groups (Supplemental Table 1). Similar to our findings 
in ACS patients, the levels of Fas, Bim and Bax were significantly lower in CD28null T cells from 
SA patients in comparison to conventional CD28+ T cells (Supplemental Figure 5). We next 
compared the levels of these pro-apoptotic molecules on CD28null T cells from ACS versus SA 
patients. Importantly, we found that Bim and Bax levels were significantly lower in CD28null T 
cells from ACS patients compared to SA patients (p<0.01 for Bim and p<0.001 for Bax, ACS 
(n=25) vs. SA (n=18), Figure 4A) and that the anti-apoptotic molecule Bcl-2 was higher in 
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CD28null T cells from ACS patients (p<0.05, Figure 4B). No differences were detected in the 
expression of Fas, FasL and anti-apoptotic molecule Bcl-xL in CD28null T cells between ACS and 
SA patients (Figure 4A,B). Our findings suggest that the reduction in Bim and Bax is more 
pronounced in CD28null T cells in ACS patients compared to SA and that this is accompanied by 
higher levels of the anti-apoptotic protein Bcl-2. 
ERK1/2 is activated in CD28null T cells from ACS patients. 
As the pro-apoptotic molecule Bim has a pivotal role in regulating apoptosis, we next examined the 
mechanisms that underlie the reduction in Bim levels in CD28null T cells in ACS. It has been 
suggested that post-translational modifications of Bim, such as phosphorylation, target it for 
proteasomal degradation27, thereby promoting cell survival. Activation of the ERK1/2 signalling 
pathway has been shown to promote Bim phosphorylation and proteasome-dependent degradation 
of phosphorylated Bim28. We therefore analysed ERK1/2 signalling in CD28null and CD28+ T cells 
from ACS patients. We used the PhosFlow technique, which, in comparison to standard western 
blotting, provides a direct cell-based assessment of signalling events when the number of cells 
obtainable for analysis is low, as is the case with CD28null T cells. Purified CD28null and CD28+ T 
cells were analysed either directly (resting T cells) or following activation by cross-linking CD3 
with monoclonal antibodies. We observed consistently high baseline ERK1/2 phosphorylation in 
resting CD28null T cells (Figure 5A,C). In contrast, resting CD28+ T cells exhibited low levels of 
ERK1/2 phosphorylation, which were significantly lower than those observed in resting CD28null T 
cells (p<0.001, Figure 5A,C). These results clearly demonstrate constitutive activation of ERK1/2 
in resting CD28null T cells in ACS. In vitro stimulation with anti-CD3 antibodies led to 
upregulation of phosphorylated ERK1/2 in both CD28null and CD28+ T cells (Figure 5B,C). Of 
note, even following activation the levels of phosphorylated ERK1/2 remained significantly higher 
in CD28null T cells compared to their conventional CD28+ counterparts (p<0.001, Figure 5A,C). 
Bim is phosphorylated in CD28null T cells from ACS patients. 
As mentioned, ERK1/2 activation has been shown to induce phosphorylation of Bim, which targets 
Bim for degradation via the proteasome28. We therefore assessed the expression of phosphorylated 
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Bim (phospho-Bim) in CD28null T cells in ACS patients using an antibody that recognises solely 
the phosphorylated form of human Bim. Phospho-Bim was detected in both resting CD28null and 
CD28+ T cells (Figure 6A,C). However, resting CD28null T cells expressed significantly higher 
levels of phospho-Bim than conventional CD28+ T cells (p<0.001, Figure 6A,C). Following 
activation with anti-CD3 cross-linking antibodies, phospho-Bim increased further in CD28null T 
cells, whilst in CD28+ T cells it remained unchanged (Figure 6B,C). These results support our 
hypothesis that Bim is phosphorylated in CD28null T cells, which may tag it for proteasomal 
degradation. To determine whether ERK activation plays a role in Bim phosphorylation in CD28null 
T cells, we pre-incubated purified CD28null and CD28+ T cells from ACS patients with PD184352, 
a specific ERK1/2 inhibitor29 followed by activation with anti-CD3 cross-linking antibodies in the 
continuous presence of the inhibitor and quantified phospho-Bim expression. As shown previously 
(Figure 6B), activation of CD28null T cells increased phospho-Bim levels (Figure 6E). This 
increase was abrogated by ERK1/2 inhibition with PD184352 (p<0.05, Figure 6D,E). ERK1/2 
inhibition did not affect phospho-Bim levels in CD28+ T cells (Figure 6D,E). Bim phosphorylation 
has been shown to tag the protein for degradation by the proteasome28. We therefore examined 
whether proteasome inhibition affects the levels of phospho-Bim in CD28null T cells. Treatment 
with the cell-permeable proteasomal inhibitor MG-13227 increased phospho-Bim levels in both 
resting and activated CD28null T cells (p<0.05, Figure 6E), whilst it did not have an effect on 
CD28+ T cells. 
Proteasomal inhibition restores apoptosis sensitivity of CD28null T cells in ACS. 
We have demonstrated that CD28null T cells have higher levels of activated ERK1/2 and this 
associates with Bim phosphorylation and proteasomal degradation in CD28null T cells. It has been 
shown that proteasomal degradation of phosphorylated Bim, confers apoptosis resistance by 
leaving Bcl-2 and Bcl-xL unhampered to exert their anti-apoptotic effects27. We therefore 
hypothesised that inhibiting Bim phosphorylation by blocking ERK1/2 or preventing phospho-Bim 
degradation by blocking the proteasome should restore the apoptosis sensitivity of CD28null T cells. 
To test this hypothesis we investigated the effect of the ERK1/2 inhibitor PD184352 on apoptosis 
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sensitivity of CD28null T cells in ACS patients. Purified CD28null and CD28+ T cells were induced 
to enter apoptosis by treatment with CH11 in the presence or absence of PD184352. We found that 
ERK1/2 inhibition with PD184352 did not significantly affect the apoptosis of CD28null T cells in 
response to CH11 (Figure 7). Even though we observed a trend towards an increase in the 
percentage of early apoptotic CD28null T cells this did not reach statistical significance (Figure 7). 
Next we investigated the effect of proteasome inhibition on CD28null T cell apoptosis. For this, 
cells were treated with CH11 in the presence or absence of the cell-permeable proteasomal 
inhibitor MG-132. MG-132 on its own did not affect the viability of CD28null and CD28+ T cells 
which were not treated with CH11 (Figure 8A,B). Importantly, MG-132 significantly increased 
apoptosis of CD28null T cells treated with CH11 (p<0.01, Figure 8A,B). This was true for both 
early and late apoptotic CD28null T cells. Of note, MG-132 did not influence the apoptosis of 
CD28+ T cells treated with CH11 (Figure 8A,B), suggesting that it did not affect the viability of 
conventional CD28+ T cells.  
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Discussion 
Here we report that CD28null T cells from ACS patients harbour important alterations in apoptosis 
that could explain their accumulation. We demonstrate for the first time that in ACS patients 
CD28null T cells are endowed with resistance to apoptosis induction both via the death receptor 
(Fas-mediated) and mitochondrial (ceramide-mediated) pathways. Moreover, we show that the 
molecular basis for the loss of apoptosis sensitivity in CD28null T cells is a marked reduction in pro-
apoptotic molecules Bim and Bax and death receptor Fas. Critically, we propose a novel 
mechanism that links Bim phosphorylation and its degradation by the proteasome as the key event 
that governs the loss of apoptosis sensitivity in CD28null T cells. In addition, we present promising 
new results that demonstrate for the first time that apoptosis sensitivity of CD28null T cells can be 
reinstated by proteasomal inhibition. 
T cell sensitivity to apoptosis is tightly regulated and the intricate mechanisms controlling this 
process have not been completely deciphered. Here we show for the first time that CD28null T cells 
from ACS patients are resistant to apoptosis induction and that they exhibit reduced levels of pro-
apoptotic molecules Bim and Bax and death receptor Fas, compared to conventional CD28+ T 
cells. Changes in levels of members of the Bcl-2 family and their interactions have long been 
recognised to regulate survival of T cells16. In particular, Bim has pivotal roles in controlling the 
fine balance between pro-apoptosis and pro-survival molecules in various cells, including T cells30. 
However, the role of Bim in CD28null T cells has not been previously investigated. Bim acts as an 
initiator of apoptosis and although it does not trigger apoptosis itself, it enables Bax to induce cell 
death30. In viable cells, the pro-apoptotic function of Bax is inhibited by binding to anti-apoptotic 
molecules (Bcl-2 and Bcl-xL)31. In response to death signals, Bim translocates from the 
cytosol/cytoskeleton to the mitochondria and binds to Bcl-2, displacing it from its complex with 
Bax, which in turn releases Bax to trigger apoptosis. Thus Bim is crucial for the pro-apoptotic 
action of Bax30. Our finding that CD28null T cells in ACS have significantly reduced levels of both 
Bim and Bax suggests that in these cells the anti-apoptotic activity of Bcl-2/Bcl-xL is left 
unopposed by pro-apoptotic signals from Bim and Bax, which may endow CD28null T cells with 
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apoptosis resistance and give these cells a survival advantage. This is supported by other studies 
which report that induction of either Bim or Bax counteracts Bcl-2 anti-apoptotic signals and can 
enable apoptosis even when Bcl-2 levels are maintained30. Furthermore, deletion of Bim and Bax 
inhibited the death of murine T cells in knock-out models32,33. Bim has also been suggested to 
collaborate with Fas in the control of T cell homeostasis and elimination of unwanted T cells34,35. 
Mice deficient in both Bim and Fas accumulate more T cells and display severe autoimmunity 
compared to those deficient in either Bim or Fas that develop mild autoimmune phenomena36. Of 
note, we found that freshly analysed CD28null T cells from ACS patients had low levels of both 
Bim and Fas, which may suggest a pronounced defect in apoptosis sensitivity in these cells. 
Moreover, the levels of Bim, Bax and Fas stayed low even when CD28null T cells were cultured in 
vitro. Interestingly, following in vitro activation, which is known to increase the sensitivity of T 
cells to apoptosis, Fas increased on CD28null T cells to levels comparable to CD28+ T cells, while 
Bim and Bax remained significantly low. These findings suggest that Bim and Bax are the major 
drivers of apoptosis resistance in CD28null T cells. 
Our results show that anti-apoptotic molecules Bcl-2 and Bcl-xL are expressed at similar levels in 
CD28null and CD28+ T cells in ACS patients, implying that these molecules do not have a central 
role in apoptosis resistance of CD28null T cells. Our findings are in contrast to data on CD28null T 
cell clones from patients with rheumatoid arthritis (RA) 37,38, another disease in which this subset 
expands. These studies reported an increase in Bcl-2 in CD28null T cell lines and clones compared 
to lines and clones derived from CD28+ T cells. In addition, they did not identify any differences in 
Fas, Bcl-xL and Bax between CD28null and CD28+ T cell lines, whilst Bim was not investigated. 
Bcl-2 upregulation reported in these studies on RA patients could be explained by use of CD28null 
T cell lines/clones, instead of analysing fresh primary T cells (as was done in our study on ACS 
patients). Clonal expansion alters the levels of pro- and anti-apoptotic molecules, as cells are 
subjected to several rounds of activation in vitro, aimed at extending their life in culture and 
therefore may not be representative of the apoptosis sensitivity of these cells in vivo.  
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It has been suggested that Rosuvastatin may induce apoptosis of CD28null T cells in ACS patients37. 
In our hands, direct treatment of pure populations of CD28null and CD28+ T cells from ACS 
patients with increasing doses of Atorvastatin or Rosuvastatin did not induce apoptosis. Indeed 
many ACS patients who are already on statin therapy still exhibit high numbers of CD28null T cells 
and previous reports showed that CD28null T cell frequency remained unchanged for up to two 
years after an acute coronary event although statins are routinely prescribed following ACS13, 
which indicate that statins do not induce apoptosis in CD28null T cells, in line with our in vitro 
findings. 
Given Bim’s central role in controlling the balance between pro- and anti-apoptotic signals, we 
investigated the mechanisms responsible for Bim reduction in CD28null T cells. Previous studies on 
cancer cell lines, fibroblasts and CD8+ T cells from OT-I transgenic mice have suggested that Bim 
can be degraded by the proteasome, following post-transcriptional modifications such as 
phosphorylation27,39. We demonstrate that ERK1/2, a protein kinase that has been implicated in 
regulating Bim levels by phosphorylating it, is constitutively activated (phosphorylated) in resting 
CD28null T cells from ACS patients, whilst conventional CD28+ T cells exhibited significantly 
lower ERK1/2 activation. In addition, we also detected higher levels of phosphorylated ERK1/2 
following activation of CD28null T cells, well above those present in CD28+ T cells. Another novel 
finding was that CD28null T cells express significantly higher levels of phosphorylated Bim than 
conventional CD28+ counterparts. In support of a role for ERK1/2 in Bim phosphorylation, we 
present data showing that ERK1/2 inhibition reduced phosphorylated Bim levels in CD28null T cells 
following activation via CD3 cross-linking. Bim phosphorylation has been shown to tag this 
protein for degradation by the proteasome, which may explain the marked reduction in Bim that 
characterises CD28null T cells in ACS patients. In support of this, we demonstrated that proteasome 
inhibition increased phosphorylated Bim levels in both resting and activated CD28null T cells, 
confirming a central role for the proteasome in Bim regulation. 
Next we sought a method to restore apoptosis sensitivity of CD28null T cells while sparing the 
conventional T cells. We tested two strategies: (i) ERK1/2 inhibition to prevent Bim 
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phosphorylation; and (ii) proteasome inhibition to prevent phospho-Bim degradation. We 
demonstrate that treatment with the proteasomal inhibitor MG-132 restored apoptosis sensitivity of 
CD28null T cells to CH11 in ACS patients. Encouragingly, proteasomal inhibition did not alter 
apoptosis of conventional T cells. Proteasomal inhibitors have been used to sensitise cancer cells to 
apoptosis. Of note, the dose of proteasomal inhibitor that restored apoptosis sensitivity in CD28null 
T cells was in the nano molar range, approximately a thousand times lower than the doses used to 
induce apoptosis in cancer cells, suggesting that re-sensitisation of CD28null T cells to apoptosis 
could potentially be achieved in vivo in ACS at much lower doses of proteasomal inhibitors than 
those used for elimination of malignant cells, with lower side effect profile. This makes the 
proteasome an attractive target for selective elimination of CD28null T cells, while sparing their 
conventional counterparts and preventing bystander immunosupression.  
In our hands, ERK inhibition failed to significantly alter apoptosis sensitivity of CD28null T cells 
from ACS patients. This suggests that proteasomal degradation of Bim in CD28null T cells is not 
solely controlled by ERK1/2, as is the case for other cells such as CD8+ T cells from OT-I 
transgenic mice. Indeed, we found that ERK1/2 inhibition failed to affect the levels of phospho-
Bim in resting CD28null T cells, in which we showed that ERK is constitutively activated. 
Interestingly, ERK inhibition abrogated de novo induced Bim phosphorylation upon activation of 
CD28null T cells. In contrast, proteasomal inhibition increased phospho-Bim levels in both resting 
and activated CD28null T cells. This may explain why proteasomal inhibition was more effective at 
restoring apoptosis sensitivity in CD28null T cells than ERK1/2 inhibition. Additionally, one cannot 
exclude that other protein kinases may contribute to Bim phosphorylation in resting CD28null T 
cells, which will be explored in future work. 
In summary, we show that CD28null T cells in ACS patients exhibit resistance to apoptosis as a 
result of a reduction in pro-apoptotic molecules Bim, Bax and Fas and we propose a novel strategy 
to restore apoptosis sensitivity in CD28null T cells via proteasome inhibition.  As ACS patients who 
harbour high numbers of CD28null T cells have increased risk for recurrent severe acute coronary 
events and poor prognosis, deciphering the regulation of life and death decisions in CD28null T cells 
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will be useful not only in understanding the behaviour of this unique T cell subset but may also 
have potential therapeutic implications. 
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Figure legends 
Figure 1. CD4+CD28null T cells from ACS patients display reduced apoptosis in response to 
CH11. CD4+CD28null (28null) and conventional CD4+CD28+ (28pos) T cells isolated from ACS 
patients (n=18) were cultured alone (w/o) or in the presence of the Fas ligating antibody CH11 
antibody for 20 hours. Apoptosis was quantified using Annexin-V (AxV) and 7-AAD; cells in 
early stages of apoptosis were identified as AxV+7-AAD-, while cells in late stages of apoptosis 
were AxV+7-AAD+; total apoptosis was calculated as the sum of early and late apoptotic cells. A. 
Representative dot plots depicting AxV/7-AAD staining. Numbers indicate percentage of cells in 
each quadrant. B. Percentage of apoptotic cells in the same patient as in A. C. Apoptosis induction 
(calculated as described in Methods) in CD28null and CD28pos T cell subsets (n=18). **p<0.005; 
***p<0.001 (Wilcoxon matched-pairs signed rank test) 
Figure 2. CD4+CD28null T cells from ACS patients display reduced apoptosis in response to 
ceramide. CD4+CD28null (28null) and conventional CD4+CD28+ (28pos) T cells isolated from 
ACS patients (n=10) were cultured alone (w/o) or in the presence of the apoptosis inducing reagent 
C2-ceramide for 20 hours. Apoptosis was detected as in Figure 1. A. Representative dot plots 
depicting AxV/7-AAD staining. Numbers indicate percentage of cells in each quadrant. B. 
Percentage of apoptotic CD28null and CD28pos T cells in the same patient as in A. C. Apoptosis 
induction (calculated as described in Methods) in CD28null and CD28pos T cell subsets (n=10). 
*p<0.05; **p<0.005 (Wilcoxon matched-pairs signed rank test) 
Figure 3. CD4+CD28null T cells from patients with acute coronary syndrome (ACS) have 
reduced levels of Fas, Bim and Bax. Blood samples from ACS patients (n=25) were stained 
directly ex vivo for the expression of CD4, CD28, pro-apoptotic (Fas, FasL, Bim, Bax) and anti-
aapoptotic (Bcl-2, Bcl-xL) molecules and analysed by flow cytometry (as detailed in Methods). A. 
Representative dot plots display the gating strategy for CD4+CD28null (28null) and conventional 
CD4+CD28+ (28pos) T cells, with numbers indicating percentage of cells in each gate. Histogram 
plots depict expression of apoptotic molecules on gated 28null (grey) and 28+ (white) T cells or 
control samples labelled with isotype-matched antibodies (28null, dotted; 28pos, dashed). Numbers 
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represent the mean fluorescence intensity (MFI) for the indicated apoptotic molecules (grey, 
28null; black, 28pos). B. MFI of pro- and anti-apoptotic molecules in 28null and 28pos T cells 
(n=25; horizontal bar, mean value). ***p<0.001 (t-test). a.u.=arbitrary units; ns=not significant 
Figure 4. CD4+CD28null T cells from ACS patients have lower levels of Bim and Bax 
compared to SA patients. Levels of pro- (Fas, FasL, Bim, Bax) and anti- apoptotic (Bcl-2, Bcl-
xL) molecules on CD4+CD28null (28null) T cells from ACS (n=25) and SA (n=18) patients were 
compared. A. MFI values for Fas, Bim and Bax in 28null T cells. B. MFI values for FasL, Bcl-2 and 
Bcl-xL in 28null T cells. *p<0.05; **p<0.01; ***p<0.001 (t-test); horizontal bar, mean value; 
MFI=mean fluorescence intensity; a.u.=arbitrary units; ns=not significant 
Figure 5. CD4+CD28null T cells from ACS patients exhibit ERK1/2 activation. CD4+CD28null 
(28null) and conventional CD4+CD28+ (28pos) T cells were isolated from ACS patients (n=6). 
Phosphorylation of ERK1/2 was quantified by PhosFlow method before (w/o) and after activation 
of cells by CD3 cross-linking (aCD3). A. ERK1/2 phosphorylation in resting (w/o) and activated 
(aCD3) 28null (grey histograms) and 28pos (white histograms) T cells. Dotted or dashed line 
histograms indicate isotype controls for 28null and 28pos T cells, respectively. B. Histograms depict 
the effect on ERK1/2 phosphorylation of T cell activation via CD3 cross-linking in 28null and 28pos 
T cells. C. Percentage (left panel) and MFI (right panel) of phosphorylated ERK1/2 (mean±SD) in 
resting (w/o) and activated (aCD3) 28null and 28pos T cells in the patients studied (n=6). ***p<0.001 
(ANOVA and post-test Bonferroni multiple comparisons); MFI=mean fluorescence intensity; 
a.u.=arbitrary units 
Figure 6. Bim is phosphorylated in CD4+CD28null T cells from ACS patients. CD4+CD28null 
(28null) and conventional CD4+CD28+ (28pos) T cells were isolated from ACS patients (n=6) and 
Bim phoshorylation was detected with a phosphorylation site-specific antibody before (w/o) and 
after activation of cells by CD3 cross-linking (aCD3) (see Methods). A. Histograms depict Bim 
phoshorylation (pBim) in resting (w/o) and activated (aCD3) 28null (grey histograms) and 28pos 
(white histograms) T cells. Dotted or dashed line histograms indicate isotype controls for 28null and 
28pos T cells, respectively. B. Histograms depict the effect on Bim phosphorylation of T cell 
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activation via CD3 cross-linking in 28null and 28pos T cells. C. MFI of phosphorylated Bim (pBim) 
(mean±SD) in resting (w/o) and activated (aCD3) 28null and 28pos T cells in the patients studied 
(n=6). Cells were pre-treated with the ERK1/2 specific inhibitor PD184352 (PD) or with the 
proteasomal inhibitor MG-132 (MG) followed by activation with anti-CD3 antibodies (aCD3) in 
the continued presence of the inhibitors. D. Histograms depict the effect of PD treatment (grey 
histogram) on Bim phophorylation in resting (w/o) and activated (aCD3) 28null and 28pos T cells. E. 
MFI of phosphorylated Bim (pBim) in 28null and 28pos T cells treated as indicated in the patients 
studied. ***p<0.001 (ANOVA and post-test Bonferroni multiple comparisons); MFI=mean 
fluorescence intensity; a.u.=arbitrary units 
Figure 7. ERK1/2 inhibition did not alter apoptosis sensitivity of CD4+CD28null T cells from 
ACS patients. CD4+CD28null (28null) and conventional CD4+CD28+ (28pos) T cells were isolated 
from ACS patients (n=6). Cells cultured alone (w/o) or treated with CH11 to induce apoptosis were 
incubated in the presence or absence of the ERK1/2 specific inhibitor PD184352 (PD). Apoptosis 
was detected as in Figure 1. A. Representative dot plots depicting AxV/7-AAD staining. Numbers 
indicate percentage of cells in each quadrant. Bar graphs display percentage of apoptotic 28null and 
28pos T cells with various treatments in the same patient as in A. B. Graphs depict the normalised 
percentage of apoptotic cells (mean±SD; n=6). The percentage of apoptotic 28pos T cells in samples 
treated with CH11 alone was normalised to 100 (as detailed in Methods). ns=not significant 
(ANOVA and post-test Bonferroni multiple comparisons) 
Figure 8. Proteasome inhibition restores apoptosis sensitivity of CD4+CD28null T cells from 
ACS patients. CD4+CD28null (28null) and conventional CD4+CD28+ (28pos) T cells were isolated 
from ACS patients (n=6). Cells cultured alone (w/o) or treated with CH11 to induce apoptosis were 
incubated in the presence or absence of the proteasomal inhibitor MG-132 (MG). Apoptosis was 
detected as in Figure 1. A. Representative dot plots depicting AxV/7-AAD staining. Numbers 
indicate percentage of cells in each quadrant. Graph bars display the percentage of apoptotic 28null 
and 28pos T cells with various treatments in the same patient as in A. B. Graphs depict the 
normalised percentage of apoptotic cells (mean±SD; n=6). The percentage of apoptotic 28pos T 
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cells in samples treated with CH11 alone was normalised to 100 (as detailed in Methods). 
**p<0.01 (ANOVA and post-test Bonferroni multiple comparisons) 
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2Supplemental Table 1. Baseline patients’ characteristics of the study population.
ACS SA p-­value
Patients (n) 25 18
Age, years (mean±SD) 67.7±15.7 72±7.8 0.25
Gender % (male/female) 58/42 72/28 0.35
Ethnicity % (C/A)* 87/13 66/33 0.10
Family history of CAD (%) 30 16 0.05
Diabetes (type 2) (%) 34 61 0.07
Hypertension (%) 63 88 0.05
Smoking (%) 30 5 0.05
Hypercholesterolemia (%) 55 78 0.12
Prior MI† (%) 25 28 0.84
Prior CABG‡ (%) 4 17 0.17
Prior PCI§ (%) 21 44 0.10
Cholesterol (mmol/L) (mean±SD) 4.1±1.14 3.7±0.81 0.29
LDL (mmol/L) (mean±SD) 2.5±0.95 1.92±0.74 0.05
HDL (mmol/L) (mean±SD) 1.1±0.36 1.14±0.24 0.65
Triglycerides 1.24±0.75 1.5±0.83 0.33
Aspirin (%) 83 72 0.39
Statin (%) 70 55 0.30
*C/A, Caucasian/Asian;; †MI, myocardial infarction;; ‡CABG, coronary artery bypass
grafting;; §PCI, percutaneous coronary intervention
3Supplemental figure legends.
Supplemental Figure 1. Purity of sorted CD4+CD28null and conventional CD4+CD28+ T cells
from ACS patients. CD4+CD28null (28null) and conventional CD4+CD28+ (28pos) T cells were
isolated from ACS patients using negative selection of CD4+ T cells followed by positive selection
of 28+ T cells (as detailed in Supplemental Methods). The percentages of 28null and 28pos T cells in
fresh blood samples and the enriched fractions were determined by staining with monoclonal
antibodies for CD4 and CD28. The plots illustrate data from two ACS patients (A, ACS001 and B,
ACS002).
Supplemental Figure 2. Statins do not induce apoptosis in CD4+CD28null T cells from ACS
patients. CD4+CD28null (28null) and conventional CD4+CD28+ (28pos) T cells were isolated from
ACS patients (n=4). Cells were cultured alone (w/o) or treated with increasing concentrations
(5?g/ml, 10?g/ml, 30?g/ml and 90ug/ml) of Atorvastatin (AT) or Rosuvastatin (RO). Apoptosis
was quantified using Annexin-­V (AxV) and 7-­AAD following 48h of culture. A. Representative
plots from 28null and 28pos T cells treated with Atorvastatin or incubated alone (w/o). Percentage of
apoptotic cells (mean±SD) in 28null and 28pos T cells for the specified treatments in the patients
studied (n=4). B. Representative plots and cumulative data from 28null and 28pos T cells incubated
alone (w/o) or in the presence of Rosuvastatin.
Supplemental Figure 3. CD4+CD28null T cells from ACS patients proliferate less than
conventional CD4+CD28+ T cells. CD4+CD28null (28null) and conventional CD4+CD28+ (28pos)
T cells were isolated from ACS patients (n=5). T cells were labelled with CFSE and stimulated
with anti-­CD3 antibodies to induce T cell activation. Cells were cultured for four days and CFSE
dilution was assessed by flow cytometry. A. Histogram plots illustrate CFSE dilution;; the linear
gates indicate the percentage of cells that have undergone CFSE dilution. B. Percentage of cells
that have undergone CFSE dilution (mean±SD) from pooled experiments (n=5). *p,0.05;;
***p<0.001 (ANOVA and post-­test Tukey multiple comparisons)
Supplemental Figure 4. Bim and Bax failed to be induced on CD4+CD28null T cells following
activation. Peripheral blood mononuclear cells from ACS patients (n=18) were cultured alone
(w/o) or stimulated with anti-­CD3 antibodies (aCD3) to induce T cell activation. Levels of pro-­
(Fas, FasL, Bim, Bax) and anti-­apoptotic (Bcl-­2, Bcl-­xL) molecules were detected on day four of
culture. A, B, C. MFI of Fas, Bim and Bax in CD4+CD28null (28null) and conventional
CD4+CD28+ (28pos) T cells in the patients studied (n=18;; horizontal bar, mean values). D, E, F.
MFI of FasL, Bcl-­2 and Bcl-­xL in the two T cell subsets. *p<0.05;; **p<0.01;; ***p<0.001
(ANOVA and post-­test Tukey multiple comparisons);; MFI=mean fluorescence intensity;;
a.u.=arbitrary units;; ns=not significant
4Supplemental Figure 5. Pro-­apoptotic molecules Fas, Bim and Bax levels are reduced on
CD4+CD28null T cells in patients with stable angina (SA). Levels of pro-­ (Fas, FasL, Bim, Bax)
and anti-­apoptotic (Bcl-­2, Bcl-­xL) molecules on CD4+CD28null (28null) and conventional
CD4+CD28+ (28pos) T cells were quantified in fresh blood samples from SA patients (n=18). A.
MFI of Fas, Bim and Bax in 28null and 28pos T cells in the patients studied (n=18;; horizontal bars,
mean values). B. MFI of FasL, Bcl-­2 and Bcl-­xL in the two T cell subsets. *p<0.05;; **p<0.01;;
***p<0.001 (t-­test);; MFI=mean fluorescence intensity;; a.u.=arbitrary units;; ns=not significant
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Supplemental Figure 2. Statins do not induce apoptosis in CD4+CD28null T cells from ACS patients. CD4+CD28null (28null) and
conventional CD4+CD28+ (28pos) T cells were isolated from ACS patients (n=4). Cells were cultured alone (w/o) or treated with increasing
concentrations (5?g/ml, 10?g/ml, 30?g/ml and 90ug/ml) of Atorvastatin (AT) or Rosuvastatin (RO). Apoptosis was quantified using Annexin-­V
(AxV) and 7-­AAD following 48h of culture. A. Representative plots from CD28null and CD28pos T cells treated with Atorvastatin or incubated
alone (w/o). Percentage of apoptotic cells (mean?SD) in CD28null and CD28pos T cells for the specified treatments in the patients studied
(n=4). B. Representative plots and cumulative data from CD28null and CD28pos T cells incubated alone (w/o) or in the presence of
Rosuvastatin.
Supplemental Figure 3
Supplemental Figure 3. CD4+CD28null T cells from ACS patients proliferate less than conventional CD4+CD28+ T cells. CD4+CD28null
(28null) and conventional CD4+CD28+ (28pos) T cells were isolated from ACS patients (n=5). T cells were labelled with CFSE and stimulated with
anti-­CD3 antibodies to induce T cell activation. Cells were cultured for four days and CFSE dilution was assessed by flow cytometry. A. Histogram
plots illustrate CFSE dilution;; the linear gates indicate the percentage of cells that have undergone CFSE dilution. B. Percentage of cells that have
undergone CFSE dilution (mean?SD) from pooled experiments (n=5). *p,0.05;; ***p<0.001 (ANOVA and post-­test Tukey multiple comparisons)
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cells from ACS patients (n=18) were cultured alone (w/o) or stimulated with anti-­CD3 antibodies (aCD3) to induce T cell activation. Levels of pro-­
(Fas, FasL, Bim, Bax) and anti-­apoptotic (Bcl-­2, Bcl-­xL) molecules were detected on day four of culture. A, B, C. MFI of Fas, Bim and Bax in
CD4+CD28null (28null) and conventional CD4+CD28+ (28pos) T cells in the patients studied (n=18;; horizontal bars, mean values). D, E, F. MFI
of FasL, Bcl-­2 and Bcl-­xL in the two T cell subsets. *p<0.05;; **p<0.01;; ***p<0.001 (ANOVA and post-­test Tukey multiple comparisons);;
MFI=mean fluorescence intensity;; a.u.=arbitrary units;; ns=not significant
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Supplemental Figure 5. Pro-­apoptotic molecules Fas, Bim and Bax levels are reduced on CD4+CD28null T cells in patients with stable
angina (SA). Levels of pro-­ (Fas, FasL, Bim, Bax) and anti-­apoptotic (Bcl-­2, Bcl-­xL) molecules on CD4+CD28null (28null) and conventional
CD4+CD28+ (28pos) T cells were quantified in fresh blood samples from SA patients (n=18). A. MFI of Fas, Bim and Bax in 28null and 28pos T
cells in the patients studied (n=18;; horizontal bars, mean values). B. MFI of FasL, Bcl-­2 and Bcl-­xL in the two T cell subsets. *p<0.05;; **p<0.01;;
***p<0.001 (t-­test);; MFI=mean fluorescence intensity;; a.u.=arbitrary units;; ns=not significant
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